Research programme: malaria protease inhibitors - Dendreon
Alternative Names: Compound 9050; Cysteine protease inhibitors research programme - Dendreon; Malaria protease inhibitors research programme - DendreonLatest Information Update: 16 May 2007
At a glance
- Originator Dendreon Corporation
- Class
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 20 Jan 2004 A preclinical study has been added to the Parasitic Infections pharmacodynamics section
- 05 Jan 2004 The activities of Dendreon San Diego LLC are being relocated to Dendreon's Seattle headquarters
- 04 Aug 2003 Corvas International has been acquired by Dendreon Corporation and is now called Dendreon San Diego LLC